Abstract: The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter.

Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.

Abstract: Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.

Abstract: Fertilizers with urease inhibitors and/or nitrification inhibitors are described. The fertilizer can include an extruded granule containing urea, a polymeric binder, and a nitrification inhibitor and/or an urease inhibitor.

Abstract: Disclosed is a hollow fiber membrane module including a case and a hollow fiber membrane built in the case, wherein the hollow fiber membrane contains a polysulfone-based polymer and a hydrophilic polymer, and satisfies the following (A) and (B), and an amount of an eluted substance contained in a liquid obtained by circulating ultrapure water heated at 37° C. through a passage of an inner surface side of the hollow fiber membrane for 4 hours at 200 mL/min is 1.0 mg/m2 or less: (A) an insoluble component accounts for less than 3% by mass of the total mass of the hollow fiber membrane when the hollow fiber membrane is dissolved in N,N-dimethylacetamide; and (B) a flexible layer exists on a surface of a functional layer in a wet state and the flexible layer has a thickness of 7 nm or more.

Abstract: Botanical materials are dehydrated, ruptured and comminuted into particles by blades or whips in a fluidized bed. Particles separated from a drying gas are transferred to reduced pressure insulated vessels. Solvents dissolve components of the particles under precise temperature control. Solvents are recirculated and distilled to recover distillates. Distillates are refined by thermal and pressure changes to remove fats, waxes and contaminants and are fractionated to specific essential oils. The essential oils are tested, winterized, filtered, decarboxilated, polished, diluted and discharged into collection vessels. The collected essential oils are pumped through needles into sealed cartridges. The cartridges are tamper-proofed, printed and labeled with batch, botanical source, process, tracking and tracing information and codes.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.

Abstract: The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Abstract: The present disclosure is directed to compositions including a microemulsion comprising lecithin, a polysorbate, an alkyl polyglycoside, and optionally a solvent. Uses of the microemulsions are also disclosed.

Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

Abstract: The present invention provides a method for preparing an injectable thermosensitive hydrogel for preventing adhesion including mixing methyl cellulose, polyethylene glycol, oxidized cellulose nanofibers and carboxymethyl cellulose. The injectable thermosensitive hydrogel for preventing adhesion is a sol at a low temperature and induces rapid gelation upon in vivo implantation due to thermosensitivity. In addition, the hydrogel can be rapidly changed into physical hydrogel without separate additives or chemical reaction during in vivo condition. In addition, the injectable thermosensitive hydrogel for preventing adhesion exhibits excellent biodegradability and biocompatibility, has no cytotoxicity, inhibits in vitro migration of rat bone marrow mesenchymal stem cells (rBMSCs), and exhibits anti-adhesion efficacy in a rat model of sidewall defect-cecum abrasion in vivo, thus being useful as an effective anti-adhesive agent.

Abstract: A process is described for preparing a composition in the form of an emulsion that includes a high concentration of one or more avermectins. This process can include partitioning the avermectin between an active phase, including at least one glycol, and an oily phase of the emulsion. A composition thus obtained, is also described that can be used in the treatment of dermatological disorders such as rosacea.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin ?8?1 is used. In addition, used is an antagonist containing an anti-integrin ?8?1 antibody that specifically binds to at least one amino acid in a cap subdomain of an integrin ?8 chain and a periphery thereof. Also, used is an anti-fibrosis agent containing an anti-integrin ?8?1 antibody that specifically binds to R120 of an integrin ?8 chain and a periphery thereof or S132 and a periphery thereof. Note that the above antagonists may each be an anti-integrin ?8?1 antibody capable of binding to any of integrins ?8?1 derived from a human, mouse, and rat.

Abstract: The disclosure provides dermal patch formulations that include a pharmaceutically active agent, such as one or more cannabinoids. The formulations can include dihydromyricetin for the purpose of increasing the flux of the pharmaceutical agent into human skin.

Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.

Abstract: Combination compositions comprising self-assembling peptides and payload agents, and methods of making and using such compositions, are described.

Abstract: The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.

Abstract: There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

Abstract: The present disclosure relates to a sprayable gel composition, comprising (a) from about 0.08% to about 1.8% by weight of a polysaccharide, (b) from about 0.002% to about 0.08% by weight of a divalent alkaline earth cation, (c) from about 0.1% to about 30% by weight of a humectant, (d) from 0% to about 30% by weight of an emollient, and (e) from about 40% to about 95% by weight of a cosmetically acceptable carrier, wherein the weight percentages are based on the total weight of all components of the sprayable gel composition, and to a method of treating hair in need of a conditioning treatment.

Abstract: Star block copolymers having 3 to 8 arms are formed as a 3D foam scaffold having tailor-made pore sizes that mimic an actual cell size of a specific animal and/or human tissue and/or organs. The pore sizes are made within the elastomeric foams via a salt leaching process wherein a salt of a specific particle size is blended within the star block copolymers and crosslinked as by polyisocyanate compounds. Water or other suitable solvent are utilized to dissolve and leach out the salt leaving an open pore system. Animal and/or human cells are then injected into the 3D elastomeric foam scaffold that contains pendant liquid crystals on the star block copolymer whereby with the aid of nutrients, cells are formed within the pore system that are viable for at least three months. The size of the pore is predetermined to produce a desired cultured cell having a desired size.

Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds. The present invention specifically provides a novel vaccine formulation suitable for ocular immunization comprising a subunit vaccine antigen in an amount to provoke a protective immune response and at least two adjuvants of which one is corpuscular. It further provides a method for inducing a local and systemic immune response and methods for preventing recurrence of ocular infections and/or modulates the occurrence and/or severity of sequels.

Abstract: The present invention relates to agrochemical combinations having enhanced rainfastness comprising a dithiocarbamate, a polycarboxylate salt and optionally one or more pesticides and/or a plant growth regulator and/or a micronutrient.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The present invention concerns a method for obtaining an implantable cartilage gel for tissue repair of hyaline cartilage, comprising particles of chitosan hydrogel and cells that are capable of forming hyaline cartilage, said method comprising a step for amplification of primary cells in a three-dimensional structure comprising particles of physical hydrogel of chitosan or a chitosan derivative, then a step for re-differentiation and induction of the synthesis of extracellular matrix by said amplified cells, in the same three-dimensional structure, wherein said cells are primary articular chondrocytes and/or mesenchymal stem cells differentiated into chondrocytes. The present invention also concerns the cartilage gel obtained thereby, and its various uses for cartilage repair following a traumatic lesion or an osteoarticular disease such as osteoarthritis.

Abstract: Disclosed herein are a cocoon-based, vascular patch and a method for manufacturing the same. The cocoon-based, vascular patch is manufactured by dividing a cocoon into two or more fragments in a predetermined form, the cocoon having a shell having a predetermined thickness. The cocoon-based vascular patch can be relatively simply manufactured in a more cost efficient manner than conventional vascular patches, and has excellent cell growth potential and biocompatibility.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substiuted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.

Abstract: The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.

Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.

Abstract: Disclosed herein are a cocoon-based, dental barrier membrane for guided bone regeneration and a method for manufacturing the same. The cocoon-based, dental barrier membrane is manufactured by dividing a cocoon into two or more fragments in a predetermined form, the cocoon having a shell having a first thickness. The dental barrier membrane is biocompatible, has excellent tensile strength and porosity, and promotes osteogenesis in a bone defect.

Abstract: An injectable carboxymethylcellulose (CMC) and methylcellulose (MC) hydrogel derived from the plant-based polysaccharide, cellulose, is provided which gels in situ and repairs the intervertebral disc in the spinal column or other cartilaginous tissues. One specific application is for replacement of the nucleus pulposus (NP), the central gelatinous region of the intervertebral disc, following injury or degeneration.

Abstract: Processes for preparing porous particles are disclosed, in which the resulting particles release an encapsulated active ingredient more readily in aqueous media than they do in alcoholic media. Also described are the particles themselves, as well as tamperproof, abuse-deterrent, dosage forms comprising the porous particles. The release characteristics of the porous particles make them useful for overcoming drug-abuse techniques, such as dose-dumping in alcoholic media.

Abstract: The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.

Abstract: The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be shaped into 3-dimensional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.

Abstract: The present invention provides: a composition for transarterial chemoembolization, comprising two types of biodegradable microbeads having different anticancer drug release characteristics; and a preparation method therefor. According to the present invention, a composition for transarterial chemoembolization exhibiting a desired anticancer drug release characteristic can be effectively prepared by controlling the mixing ratio of first and second biodegradable microbeads. Therefore, the present invention can be usefully applied to the transarterial chemoembolization of liver cancer.

Abstract: The composition having hydrolyzed collagen and Manuka honey includes hydrolyzed collagen in an amount ranging from between 5% to 95% by weight and Manuka honey in an amount ranging from between 5% to not greater than 50% by weight in water. The Manuka honey can have a methylglyoxal concentration greater than 100 mg/kg, and preferably greater than 550 mg/kg.

Abstract: The present invention relates to measures for determining glucose and for diagnosing diseases based on impaired glucose metabolism. In particular the present invention relates to a device comprising a hydrogel having a glucose-binding protein and a ligand of the glucose-binding protein incorporated therein, wherein the hydrogel comprises a first hydrogel matrix made of alginate and a second hydrogel matrix which forms an interpenetrating network within the first hydrogel matrix. The invention further relates to the use of such a device for determining the glucose content in a sample and to the use of the device for diagnosing impaired glucose metabolism in a test subject.

Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure is provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.

Abstract: The invention relates to a process for improving the solubility of dry cell culture media. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using a stepwise procedure in which the amino acids present in the non-dissolving part are identified and added to a new batch in other particle sizes significantly reduces that problem.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.

Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

Abstract: The present invention provided an anticancer nano-silver composition for the treatment and prevention of cervical cancer. The composition contains nano-silver powder 3-200 mg/kg, carbomer 700-1000 mg/kg, triethanolamine 700-1000 mg/kg, glucose 2.8-3.2 g/kg, and water as remaining; of the nano-silver powder, wherein the purity of silver is ?99.99% and particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit HeLa proliferation, and cause cell death. The anticancer nano-silver composition of the present invention can be used to manufacture medicaments for the treatment and prevention of cervical cancer.

Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.

Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.